The results of the ANNOUNCE study show that olaratumab with doxorubicin does not prolong the lives of patients with soft tissue sarcoma
The results of the ANNOUNCE study show that olaratumab with doxorubicin does not prolong the lives of patients with soft tissue sarcoma